94 related articles for article (PubMed ID: 27825181)
1. Blood Group O Protects against Inhibitor Development in Severe Hemophilia A Patients.
Franchini M; Coppola A; Mengoli C; Rivolta GF; Riccardi F; Minno GD; Tagliaferri A;
Semin Thromb Hemost; 2017 Feb; 43(1):69-74. PubMed ID: 27825181
[TBL] [Abstract][Full Text] [Related]
2. ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers.
Franchini M; Coppola A; Santoro C; De Cristofaro R; Barillari G; Giordano P; Gresele P; Lassandro G; Napolitano M; Lucchini G; Luciani M; Ferretti A; Baldacci E; Riccardi F; Santoro RC; Pasca S; Zanon E; Tagliaferri A
Semin Thromb Hemost; 2021 Feb; 47(1):84-89. PubMed ID: 33525041
[TBL] [Abstract][Full Text] [Related]
3. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents.
Klarmann D; Eggert C; Geisen C; Becker S; Seifried E; Klingebiel T; Kreuz W
Transfusion; 2010 Jul; 50(7):1571-80. PubMed ID: 20210927
[TBL] [Abstract][Full Text] [Related]
4. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
5. Effect of ABO blood group on haemostatic parameters in severe haemophilia A patients performing acute moderate-intensity exercise.
Merlen C; Zourikian N; Bonnefoy A; Dubé E; Thibeault C; St-Louis J; Rivard GE
Blood Coagul Fibrinolysis; 2018 Nov; 29(7):626-635. PubMed ID: 30036280
[TBL] [Abstract][Full Text] [Related]
6. [A cross-sectional survey of coagulation factor VIII inhibitor in children with hemophilia A].
Wei Q; Li G; Tang L; Chen Z; Zhen Y; Wu X; Zhang N; Zhang J; Yu G; Wu R
Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):99-102. PubMed ID: 24739719
[TBL] [Abstract][Full Text] [Related]
7. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.
Garcia-Martínez I; Borràs N; Martorell M; Parra R; Altisent C; Ramírez L; Álvarez-Román MT; Nuñez R; Megias-Vericat JE; Corrales I; Alonso S; Vidal F
Thromb Haemost; 2020 Oct; 120(10):1395-1406. PubMed ID: 32726853
[TBL] [Abstract][Full Text] [Related]
8. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
[TBL] [Abstract][Full Text] [Related]
9. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
[TBL] [Abstract][Full Text] [Related]
10. [Frequency of factor VIII inhibitor in the patients with hemophilia A and environmental risk factors for inhibitor development].
Yan ZY; Fan LK; Li KX; Wang XY; Hua BL; Wang SJ; Zhao YQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):580-3. PubMed ID: 19968075
[TBL] [Abstract][Full Text] [Related]
11. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.
Marcucci M; Mancuso ME; Santagostino E; Kenet G; Elalfy M; Holzhauer S; Bidlingmaier C; Escuriola Ettingshausen C; Iorio A; Nowak-Göttl U
Thromb Haemost; 2015 May; 113(5):958-67. PubMed ID: 25631402
[TBL] [Abstract][Full Text] [Related]
12. [Screening and analysis of coagulation factor VIII inhibitor in patients with hemophilia A].
Zhang AL; Yang LH; Liu XE; Zhao H; Zhang JH; Dong CX; Qi XL; Qin XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):968-70. PubMed ID: 21867625
[TBL] [Abstract][Full Text] [Related]
13. Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study.
Kenet G; Bidlingmaier C; Bogdanova N; Ettingshausen CE; Goldenberg N; Gutsche S; Halimeh S; Holzhauer S; Kurnik K; Limperger V; Junker R; Nowak-Göttl U
Thromb Res; 2014 Apr; 133(4):544-9. PubMed ID: 24485400
[TBL] [Abstract][Full Text] [Related]
14. Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women.
Ay C; Thom K; Abu-Hamdeh F; Horvath B; Quehenberger P; Male C; Mannhalter C; Pabinger I
Haemophilia; 2010 Jan; 16(1):111-7. PubMed ID: 19758307
[TBL] [Abstract][Full Text] [Related]
15. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
[TBL] [Abstract][Full Text] [Related]
16. Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients.
Pinto P; Ghosh K; Shetty S
Blood Cells Mol Dis; 2014 Sep; 53(3):161-3. PubMed ID: 24824129
[TBL] [Abstract][Full Text] [Related]
17. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
[TBL] [Abstract][Full Text] [Related]
18. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
Mariani G; Kroner B;
Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
[TBL] [Abstract][Full Text] [Related]
19. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
[TBL] [Abstract][Full Text] [Related]
20. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.
Schleef M; Strobel E; Dick A; Frank J; Schramm W; Spannagl M
Br J Haematol; 2005 Jan; 128(1):100-7. PubMed ID: 15606555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
